Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Increased Ratio of CD14 ++ CD80 + Cells/CD14 ++ CD163 + Cells in the Infrapatellar Fat Pad of End-Stage Arthropathy Patients

Ma S., Murakami K., Saito R., Ito H., Murata K., Nishitani K.

Prospective Study on Osteoarthritis, Autoimmune Research, published in Front Immunol (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Immunol (2021)
Reported sample size
—
Source database
Europe PMC
PMID
34899727
PMCID
PMC8662627
DOI
10.3389/fimmu.2021.774177
Citations
6

Abstract (original English)

Objectives This study sought to identify the ratio of M1/M2 cells in the infrapatellar fat pads (IFP) and subcutaneous fat tissues (SC) of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. The clinical features of OA and RA patients treated with or without biological disease-modifying anti-rheumatic drugs (bDMARDs) were also assessed. Methods IFP and SC were collected from patients with OA and RA who are undergoing total knee arthroplasty (TKA). CD14-positive cells were then isolated from these samples. Flow cytometry was used to determine the number of CD14 ++ CD80 + cells and CD14 ++ CD163 + cells. The expression levels of lipid transcription factors, such as sterol regulatory element-binding protein 1 (SREBP1) and liver X receptor alpha (LXRA), and inflammatory cytokines were also evaluated. Results Twenty OA patients and 22 RA patients were enrolled in this study. Ten of the RA patients (45.4%) received bDAMRDs before TKA. On average, a fivefold increase in the number of CD14-positive cells and lower expression levels of SREBP1C and LXRA were observed in OA IFP relative to OA SC; however, these results were not obtained from the RA samples. The median ratio of CD14 ++ CD80 + cells/CD14 ++ CD163 + cells of OA IFP was 0.87 (0.76-1.09, interquartile range), which is higher to that of OA SC with a lower ratio ( p = 0.05835). Conclusions The quantity and quality of CD1

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
LeukocytesHumansArthritisArthritis, RheumatoidOsteoarthritis, KneeDisease SusceptibilityReceptors, Cell SurfaceInflammation MediatorsAntigens, CDAntigens, Differentiation, Myelomonocytic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research